Company / R&D Expense
SELLAS Life Sciences Group, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$19.1M
FY2024
5-year range
$9.3M / $24.0M
FY2020-FY2024
Trend
-20.5%
vs FY2023
Sector context
#198 of 210
Health Care
What the data says
Among 210 Health Care companies, SELLAS Life Sciences Group, Inc. is in the bottom 6% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $6M in FY2017 to $24M in FY2023.
Based on SEC 10-K filings.
$19M in FY2024 with a 5-year CAGR of +21.3%.
Improved from $16M to $19M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +27.2%
- 5-Year CAGR
- +21.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 210This company $19.1M Sector average $644.1M
▼
-97.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.3%, indicating consistent growth.
- In FY2024, r&d expense decreased 20.5% year-over-year.
- Ranks #198 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $19.1M | -20.5% |
| FY2023 | $24.0M | +53.2% |
| FY2022 | $15.7M | +68.9% |
| FY2021 | $9.3M | +0.0% |
| FY2020 | $9.3M | +27.4% |
| FY2019 | $7.3M | -16.9% |
| FY2018 | $8.8M | +44.5% |
| FY2017 | $6.1M | -46.8% |
| FY2016 | $11.4M | -51.7% |
| FY2015 | $23.6M | -14.7% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026